

# ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC)

## A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT04426825 ML41256

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This is an open-label, single-arm, phase II, multicenter study designed to evaluate the efficacy and safety of atezolizumab in combination with bevacizumab in PD-L1-selected patients with Stage IIIB-IV Non-Squamous NSCLC harbored EGFR mutation after EGFR TKI therapy.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT04426825 ML41256**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---